Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treating rheumatoid arthritis with tumour necrosis factor alpha blockade.

Literature DB >> 11834544

Treating rheumatoid arthritis with tumour necrosis factor alpha blockade.

Paul Emery, Maya Buch.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2002 PMID： 11834544 PMCID： PMC1122253 DOI： 10.1136/bmj.324.7333.312

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

11 in total

1. Targeted therapies in rheumatoid arthritis: the need for action.

Authors: P Emery; G Panayi; R Sturrock; B Williams
Journal: Rheumatology (Oxford) Date: 1999-10 Impact factor: 7.580

Review 2. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis.

Authors: J S Smolen; F C Breedveld; G R Burmester; B Combe; P Emery; J R Kalden; L Klareskog; R N Maini; R Numo; L B van De Putte; P L van Riel; V Rodriguez-Valverde
Journal: Ann Rheum Dis Date: 2000-07 Impact factor: 19.103

3. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

Authors: J M Bathon; R W Martin; R M Fleischmann; J R Tesser; M H Schiff; E C Keystone; M C Genovese; M C Wasko; L W Moreland; A L Weaver; J Markenson; B K Finck
Journal: N Engl J Med Date: 2000-11-30 Impact factor: 91.245

4. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors: P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal: N Engl J Med Date: 2000-11-30 Impact factor: 91.245

Review 5. Role of cytokines in rheumatoid arthritis.

Authors: M Feldmann; F M Brennan; R N Maini
Journal: Annu Rev Immunol Date: 1996 Impact factor: 28.527

6. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.

Authors: L A Joosten; M M Helsen; T Saxne; F A van De Loo; D Heinegard; W B van Den Berg
Journal: J Immunol Date: 1999-11-01 Impact factor: 5.422

7. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

Authors: L W Moreland; M H Schiff; S W Baumgartner; E A Tindall; R M Fleischmann; K J Bulpitt; A L Weaver; E C Keystone; D E Furst; P J Mease; E M Ruderman; D A Horwitz; D G Arkfeld; L Garrison; D J Burge; C M Blosch; M L Lange; N D McDonnell; M E Weinblatt
Journal: Ann Intern Med Date: 1999-03-16 Impact factor: 25.391

8. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

Authors: M J Elliott; R N Maini; M Feldmann; J R Kalden; C Antoni; J S Smolen; B Leeb; F C Breedveld; J D Macfarlane; H Bijl
Journal: Lancet Date: 1994-10-22 Impact factor: 79.321

9. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

Authors: R N Maini; F C Breedveld; J R Kalden; J S Smolen; D Davis; J D Macfarlane; C Antoni; B Leeb; M J Elliott; J N Woody; T F Schaible; M Feldmann
Journal: Arthritis Rheum Date: 1998-09